Last updated: November 18, 2023
Sponsor: Jasper Gerritsen
Overall Status: Active - Recruiting
Phase
N/A
Condition
Glioblastoma Multiforme
Gliomas
Astrocytoma
Treatment
Tumor resection
Tumor biopsy
Palliative Care
Clinical Study ID
NCT06146738
MEC-2020-0812-4
Ages 18-90 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age ≥18 years and ≤90 years
- Tumor diagnosed as HGG (WHO grade III/IV) on MRI as assessed by the neurosurgeon
- Written informed consent
Exclusion
Exclusion Criteria:
- Tumors of the cerebellum, brainstem or midline
- Inability to give written informed consent
- Secondary high-grade glioma due to malignant transformation from low-grade glioma
- Second primary malignancy within the past 5 years with the exception of adequatelytreated in situ carcinoma of any organ or basal cell carcinoma of the skin
Study Design
Total Participants: 1015
Treatment Group(s): 3
Primary Treatment: Tumor resection
Phase:
Study Start date:
January 01, 2023
Estimated Completion Date:
January 01, 2029
Study Description
Connect with a study center
University Hospital Leuven
Leuven,
BelgiumActive - Recruiting
Technical University Munich
Munich, Bavaria 74076
GermanySite Not Available
University Hospital Heidelberg
Heidelberg,
GermanyActive - Recruiting
Erasmus Medical Center
Rotterdam, Zuid-Holland 3015 GD
NetherlandsActive - Recruiting
Haaglanden Medical Centre
The Hague, Zuid-Holland 2512 VA
NetherlandsActive - Recruiting
Inselspital Universitätsspital Bern
Bern, 3010
SwitzerlandSite Not Available
University of California, San Francisco
San Francisco, California 94143
United StatesActive - Recruiting
Massachusetts General Hospital
Boston, Massachusetts 02114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.